Cargando…

Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study

INTRODUCTION: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a condition that is characterized by urgency, frequency and/or pelvic pain. The disease occurs mainly in women. BPS/IC can be severe enough to have a significant impact on patients' quality of life, but it can also be associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasyan, George, Kupriyanov, Yury, Karasev, Alexander, Baibarin, Kirill, Pushkar, Dmitry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Urological Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318027/
https://www.ncbi.nlm.nih.gov/pubmed/34336239
http://dx.doi.org/10.5173/ceju.2021.0340.R1
_version_ 1783730170500218880
author Kasyan, George
Kupriyanov, Yury
Karasev, Alexander
Baibarin, Kirill
Pushkar, Dmitry
author_facet Kasyan, George
Kupriyanov, Yury
Karasev, Alexander
Baibarin, Kirill
Pushkar, Dmitry
author_sort Kasyan, George
collection PubMed
description INTRODUCTION: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a condition that is characterized by urgency, frequency and/or pelvic pain. The disease occurs mainly in women. BPS/IC can be severe enough to have a significant impact on patients' quality of life, but it can also be associated with moderate symptoms that are equally debilitating. The aim of this article was to evaluate the possibility of the use of pentosan polysulfate sodium in patients in the complex treatment of BPS/IC. MATERIAL AND METHODS: A multicenter, double-blind, placebo-controlled, randomized study was conducted in parallel groups in 7 Russian medical centers. RESULTS: Efficacy and safety have been established as the main criteria. A total of 93 patients were screened. Statistical analysis was performed. It has been shown that pentosan therapy is more effective than in the placebo. Average change in the number of points on the scale O'Leary-Santa Interstitial Cystitis Symptom Index compared to baseline data in the pentosan group 4.93 ±3, 03, in the placebo group 1.66 ±3.19 (p = 0.014), and the adverse events and safety of pentosan are comparable to the placebo group. CONCLUSIONS: Oral glycosaminoglycan (pentosan polusulfate sodium) is an effective and safe drug and should be included in the complex treatment of patients with bladder pain syndrome/interstitial cystitis.
format Online
Article
Text
id pubmed-8318027
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Polish Urological Association
record_format MEDLINE/PubMed
spelling pubmed-83180272021-07-30 Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study Kasyan, George Kupriyanov, Yury Karasev, Alexander Baibarin, Kirill Pushkar, Dmitry Cent European J Urol Original Paper INTRODUCTION: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a condition that is characterized by urgency, frequency and/or pelvic pain. The disease occurs mainly in women. BPS/IC can be severe enough to have a significant impact on patients' quality of life, but it can also be associated with moderate symptoms that are equally debilitating. The aim of this article was to evaluate the possibility of the use of pentosan polysulfate sodium in patients in the complex treatment of BPS/IC. MATERIAL AND METHODS: A multicenter, double-blind, placebo-controlled, randomized study was conducted in parallel groups in 7 Russian medical centers. RESULTS: Efficacy and safety have been established as the main criteria. A total of 93 patients were screened. Statistical analysis was performed. It has been shown that pentosan therapy is more effective than in the placebo. Average change in the number of points on the scale O'Leary-Santa Interstitial Cystitis Symptom Index compared to baseline data in the pentosan group 4.93 ±3, 03, in the placebo group 1.66 ±3.19 (p = 0.014), and the adverse events and safety of pentosan are comparable to the placebo group. CONCLUSIONS: Oral glycosaminoglycan (pentosan polusulfate sodium) is an effective and safe drug and should be included in the complex treatment of patients with bladder pain syndrome/interstitial cystitis. Polish Urological Association 2021-05-07 2021 /pmc/articles/PMC8318027/ /pubmed/34336239 http://dx.doi.org/10.5173/ceju.2021.0340.R1 Text en Copyright by Polish Urological Association https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Kasyan, George
Kupriyanov, Yury
Karasev, Alexander
Baibarin, Kirill
Pushkar, Dmitry
Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
title Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
title_full Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
title_fullStr Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
title_full_unstemmed Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
title_short Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
title_sort safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318027/
https://www.ncbi.nlm.nih.gov/pubmed/34336239
http://dx.doi.org/10.5173/ceju.2021.0340.R1
work_keys_str_mv AT kasyangeorge safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy
AT kupriyanovyury safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy
AT karasevalexander safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy
AT baibarinkirill safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy
AT pushkardmitry safetyandefficacyofpentosanpolysulfateinpatientswithbladderpainsyndromeinterstitialcystitisamulticenterdoubleblindplacebocontrolledrandomizedstudy